Montmorillonite

Summary

Montmorillonite (CHEMBL4298106) is a phase-3 clinical-stage unknown (ATC A07BC05); indicated across 2 conditions including diarrheal disease and breast neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: A07BC05
• Indications: 2 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298106
Name	Montmorillonite
Type	Unknown
Max phase	3
ATC	A07BC05

Also known as: Diosmectite, Gelwhite gp, Gelwhite h, Gelwhite l, Montmorillonite, Montmorillonite clay, Smecdral, Smecta, MONTMORILLONITE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diarrheal disease	3	MONDO:0001673	HP:0002014
breast neoplasm	2	MONDO:0021100	MONDO:0007254

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE4	3
PHASE1	2
PHASE2	1
EARLY_PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00276328	PHASE4	COMPLETED	Study to Evaluate Smecta® vs Placebo on the Time to Recovery Following an Acute Diarrhoea Episode in Adults
NCT02704091	PHASE4	COMPLETED	Efficacy of Diosmectite (Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults
NCT04788485	PHASE4	COMPLETED	Evaluation of Smectite Effect As A Food Thickener On Gastroesophageal Reflux Disease In Neonates Using Combined Esophageal Multichannel Intraluminal Impedance
NCT02323516	PHASE2	WITHDRAWN	Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies.
NCT03045926	PHASE1	COMPLETED	Chronic Administration of Diosmectite (SMECTA®) in Subjects With Chronic Diarrhoea
NCT05252546	PHASE1	COMPLETED	Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects
NCT06588036	EARLY_PHASE1	NOT_YET_RECRUITING	A Comprehensive Analysis of the Comparative Efficacy of Multimodal Diarrhea Therapies in the Paediatric Population
NCT02124330	Not specified	COMPLETED	Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).